SA520412500B1 - مركبات لعلاج اضطرابات معتمدة على كيناز - Google Patents

مركبات لعلاج اضطرابات معتمدة على كيناز

Info

Publication number
SA520412500B1
SA520412500B1 SA520412500A SA520412500A SA520412500B1 SA 520412500 B1 SA520412500 B1 SA 520412500B1 SA 520412500 A SA520412500 A SA 520412500A SA 520412500 A SA520412500 A SA 520412500A SA 520412500 B1 SA520412500 B1 SA 520412500B1
Authority
SA
Saudi Arabia
Prior art keywords
compounds
kinase
treatment
dependent disorders
compositions
Prior art date
Application number
SA520412500A
Other languages
English (en)
Inventor
جيانج فامينج
تسو كين
كاني بانين ليني
بوي مينا
زو وي
وانج يونج
Original Assignee
إكسيليكسيس، إنك.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by إكسيليكسيس، إنك. filed Critical إكسيليكسيس، إنك.
Publication of SA520412500B1 publication Critical patent/SA520412500B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/60—Quinoline or hydrogenated quinoline ring systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

يتعلق الاختراع الحالي بالكشف عن مركبات بالصيغة I. (I) مركبات بالصيغة I تثبط، و/أو تنظِّم و/أو تعدِّل مستقبل كيناز kinase receptor ، خاصةً مسارات تحويل إشارات signal transduction pathways Axl وMer ذات الصلة بالتغيرات في الأنشطة الخلوية cellular activities كما ذكر أعلاه، وبتركيبات تحتوي على هذه المركبات، وبطرق لاستخدامها في علاج أمراض وحالات معتمدة على كيناز kinase. ويوفر الاختراع الحالي طرقًا لتصنيع مركبات كما ذكر أعلاه، وتركيبات تحتوي على هذه المركبات.
SA520412500A 2018-01-26 2020-07-23 مركبات لعلاج اضطرابات معتمدة على كيناز SA520412500B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862622702P 2018-01-26 2018-01-26
US201862758321P 2018-11-09 2018-11-09

Publications (1)

Publication Number Publication Date
SA520412500B1 true SA520412500B1 (ar) 2024-06-23

Family

ID=65409544

Family Applications (1)

Application Number Title Priority Date Filing Date
SA520412500A SA520412500B1 (ar) 2018-01-26 2020-07-23 مركبات لعلاج اضطرابات معتمدة على كيناز

Country Status (19)

Country Link
US (2) US11542259B2 (ar)
EP (1) EP3743070A1 (ar)
JP (2) JP7321165B2 (ar)
CN (5) CN117624045A (ar)
AU (2) AU2019212801B2 (ar)
BR (1) BR112020015201A2 (ar)
CA (1) CA3088200A1 (ar)
CL (1) CL2020001931A1 (ar)
CO (1) CO2020010465A2 (ar)
CR (2) CR20200358A (ar)
IL (2) IL300824A (ar)
MA (1) MA51673A (ar)
MX (2) MX2020007765A (ar)
PE (1) PE20211203A1 (ar)
PH (1) PH12020551208A1 (ar)
SA (1) SA520412500B1 (ar)
SG (1) SG11202006921PA (ar)
UA (1) UA128476C2 (ar)
WO (1) WO2019148044A1 (ar)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL300824A (en) * 2018-01-26 2023-04-01 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
US11673897B2 (en) 2018-01-26 2023-06-13 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
US11866431B2 (en) 2018-11-09 2024-01-09 Vivace Therapeutics, Inc. Bicyclic compounds
PE20211757A1 (es) * 2018-12-13 2021-09-07 Exelixis Inc Formas cristalinas y formas de sal de un inhibidor de cinasa
CN113710322A (zh) * 2019-01-25 2021-11-26 埃克塞里艾克西斯公司 用于治疗激酶依赖性病症的化合物
CN109761899B (zh) * 2019-02-14 2022-11-15 广州六顺生物科技股份有限公司 喹啉衍生物、其药学上可接受的盐或其溶剂合物、其应用、药物及药物组合物
TWI849107B (zh) 2019-04-16 2024-07-21 美商維瓦斯治療公司 雙環化合物
AU2019449809A1 (en) * 2019-06-03 2021-12-16 Exelixis, Inc. Crystalline salt forms of a kinase inhibitor
CN110845406B (zh) * 2019-12-04 2021-07-20 广州安岩仁医药科技有限公司 喹啉类化合物的制备方法
US20230150956A1 (en) * 2020-02-10 2023-05-18 Stemsynergy Therapeutics, Inc. Myc inhibitors and uses thereof
US20230192619A1 (en) * 2020-04-30 2023-06-22 Exelixis, Inc. Processes for the Preparation of a Kinase Inhibitor
JP2023536264A (ja) * 2020-07-31 2023-08-24 エグゼリクシス， インコーポレイテッド がんの治療のための組み合わせ
PE20240223A1 (es) 2020-11-05 2024-02-16 Exelixis Inc Composiciones farmaceuticas de un inhibidor de cinasa
WO2022161447A1 (zh) * 2021-02-01 2022-08-04 江苏恒瑞医药股份有限公司 二甲酰胺类化合物、其制备方法及其在医药上的应用
CN113582924A (zh) * 2021-09-09 2021-11-02 四川国康药业有限公司 一种多靶点酪氨酸激酶抑制剂及其制备方法和用途
AR127561A1 (es) * 2021-11-03 2024-02-07 Exelixis Inc Compuestos para el tratamiento de trastornos dependientes de cinasas
WO2023122739A1 (en) 2021-12-22 2023-06-29 Exelixis, Inc. Crystalline forms and salt forms of a kinase inhibitor
CN114573553B (zh) * 2022-01-27 2023-11-10 广州六顺生物科技有限公司 杂芳环类衍生物及其制备方法和应用

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
EP3103799B1 (en) 1995-03-30 2018-06-06 OSI Pharmaceuticals, LLC Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
IL126351A0 (en) 1996-04-12 1999-05-09 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
KR100600550B1 (ko) * 2000-10-20 2006-07-13 에자이 가부시키가이샤 질소 함유 방향환 유도체
EP2612853A1 (en) 2003-09-26 2013-07-10 Exelixis Inc. c-Met modulators and methods of use
US7314622B2 (en) 2005-04-15 2008-01-01 Neogenix Oncology, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
NZ563193A (en) 2005-05-09 2010-05-28 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
JPWO2007052849A1 (ja) * 2005-11-07 2009-04-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質とｃ−ｋｉｔキナーゼ阻害物質との併用
MX2011004018A (es) * 2008-10-14 2011-06-24 Ning Xi Compuestos y metodos de uso.
TWI447108B (zh) 2009-01-16 2014-08-01 Exelixis Inc Ｎ－（４－｛〔６，７雙（甲氧基）喹啉－４－基〕氧基｝苯基）－ｎ’－（４－氟苯基）環丙烷－１，１－二甲醯胺之蘋果酸鹽及其結晶型
EP2213686A1 (en) 2009-01-28 2010-08-04 Externautics S.p.A. Tumor markers and methods of use thereof
EP2214019A1 (en) 2009-01-28 2010-08-04 Externautics S.p.A. Tumor markers and methods of use thereof
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
WO2011051280A1 (en) 2009-10-26 2011-05-05 Externautics S.P.A. Ovary tumor markers and methods of use thereof
WO2011051277A1 (en) 2009-10-26 2011-05-05 Externautics S.P.A. Breast tumor markers and methods of use thereof
EP2494362B1 (en) 2009-10-26 2016-06-08 Externautics S.p.A. Prostate tumor markers and methods of use thereof
WO2011051276A1 (en) 2009-10-26 2011-05-05 Externautics S.P.A. Colon and rectal tumor markers and methods of use thereof
US20120322075A1 (en) 2009-10-26 2012-12-20 Externautics S.P.A. Lung Tumor Markers and Methods of Use Thereof
US20120070368A1 (en) * 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
EP2383578A1 (en) 2010-04-30 2011-11-02 Externautics S.p.A. Tumor marker and methods of use thereof
AU2011278832B2 (en) * 2010-07-14 2014-03-13 Betta Pharmaceuticals Co., Ltd Novel fused heterocyclic derivatives useful as c-Met tyrosine kinase inhibitors
PL2593090T3 (pl) 2010-07-16 2022-02-21 Exelixis, Inc. Kompozycje farmaceutyczne modulatora c-Met
US8664244B2 (en) * 2010-09-12 2014-03-04 Advenchen Pharmaceuticals, LLC Compounds as c-Met kinase inhibitors
ES2754973T5 (es) 2010-09-27 2023-03-13 Exelixis Inc Inhibidores duales de MET y VEGF para el tratamiento del cáncer de próstata resistente a la castración y metástasis óseas osteoblásticas
CN102093421B (zh) * 2011-01-28 2014-07-02 北京康辰药业有限公司 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
KR20210147117A (ko) 2011-02-10 2021-12-06 엑셀리시스, 인코포레이티드 퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
GEP201706678B (en) 2011-05-02 2017-06-12 Exelixis Inc Method of treating cancer and bone cancer
CN102408411B (zh) * 2011-09-19 2014-10-22 北京康辰药业股份有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
EP2758057B1 (en) 2011-09-22 2017-05-31 Exelixis, Inc. Method for treating osteoporosis
BR112014009302B1 (pt) 2011-10-20 2020-04-28 Exelis Inc Us/Us processo para preparar derivados de quinolina
AR088813A1 (es) 2011-11-08 2014-07-10 Exelixis Inc Metodo para cuantificar el tratamiento de cancer
TW201818937A (zh) 2011-11-08 2018-06-01 美商艾克塞里克斯公司 治療癌症之方法
US9861624B2 (en) 2012-05-02 2018-01-09 Exelixis, Inc. Method of treating cancer
CN114129566A (zh) 2012-09-07 2022-03-04 埃克塞里艾克西斯公司 用于治疗肺腺癌的met、vegfr和ret的抑制剂
CN104994873B (zh) 2012-10-04 2017-12-22 达纳－法伯癌症研究所公司 人单克隆抗‑pd‑l1抗体和使用方法
UA119321C2 (uk) 2013-03-15 2019-06-10 Екселіксіс, Інк. Метаболіти n-(4-{[6,7-біс(метилокси)хінолін-4-іл]окси}феніл)-n'-(4-фторфеніл)циклопропан-1,1-дикарбоксаміду
JP2016515628A (ja) 2013-04-04 2016-05-30 エグゼリクシス， インコーポレイテッド 癌を治療するための複合薬
ES2927651T3 (es) 2013-04-04 2022-11-10 Exelixis Inc Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer
SG11201508528TA (en) 2013-05-02 2015-11-27 Anaptysbio Inc Antibodies directed against programmed death-1 (pd-1)
US10359428B2 (en) 2013-06-14 2019-07-23 Externautics S.P.A. Tumor marker, monoclonal antibodies and methods of use thereof
BR112016010224A2 (pt) 2013-11-05 2018-05-02 Cognate Bioservices, Inc. combinações de inibidores do ponto de verificação e produtos terapêuticos para tratar o câncer.
CA3181899A1 (en) 2014-02-14 2015-08-20 Exelixis, Inc. Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
JP6666849B2 (ja) 2014-03-17 2020-03-18 エグゼリクシス， インコーポレイテッド カボザンチニブ製剤の投与
PL3134084T3 (pl) 2014-04-25 2021-09-27 Exelixis, Inc. Sposób leczenia gruczolakoraka płuca
WO2016019285A1 (en) 2014-07-31 2016-02-04 Exelixis, Inc. Method of preparing fluorine-18 labeled cabozantinib and its analogs
CA2957466C (en) 2014-08-05 2023-10-17 Exelixis, Inc. Drug combinations to treat multiple myeloma
CN104817497B (zh) * 2015-03-20 2017-03-08 南京众睿缘生物科技有限公司 一种炔代喹啉衍生物及其制备方法和用途
CN106279147A (zh) 2015-05-21 2017-01-04 中国科学院上海药物研究所 一种吡啶并氮杂环化合物及其制备方法和用途
US20170342033A1 (en) * 2015-06-29 2017-11-30 Ontogenesis, Llc Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use
US20180009758A1 (en) * 2015-06-29 2018-01-11 Ontogenesis, Llc Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use
CA3020749A1 (en) 2016-04-15 2017-10-19 Exelixis, Inc. Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
US20210030737A1 (en) 2016-04-19 2021-02-04 Exelixis, Inc. Triple Negative Breast Cancer Treatment Method
CN105797123A (zh) * 2016-05-18 2016-07-27 王超 一种治疗不孕不育的中药组合物
CN106400155A (zh) * 2016-08-31 2017-02-15 飞佛特种纺织品（宁波）有限公司 一种防老化阳光面料
CN107235896B (zh) * 2016-09-13 2019-11-05 上海翔锦生物科技有限公司 酪氨酸激酶抑制剂及其应用
CA3038500A1 (en) 2016-09-27 2018-04-05 Andrea B. Apolo Method of treating urothelial carcinoma and other genitourinary malignancies using n-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
AU2018210397B2 (en) 2017-01-20 2024-02-29 Exelixis, Inc. Combinations of cabozantinib and atezolizumab to treat cancer
WO2018145621A1 (zh) * 2017-02-07 2018-08-16 恩瑞生物医药科技（上海）有限公司 喹啉类化合物、其制备方法及其医药用途
CA3060370A1 (en) 2017-05-26 2018-11-29 Exelixis, Inc. Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
WO2018227119A1 (en) 2017-06-09 2018-12-13 Exelixis, Inc. Liquid dosage forms to treat cancer
CA3086522A1 (en) * 2017-12-20 2019-06-27 Angex Pharmaceutical, Inc. Carbamate and urea compounds as multikinase inhibitors
US20190262330A1 (en) 2017-12-21 2019-08-29 Exelixis, Inc. Method of Treating Hepatocellular Carcinoma Using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
US11673897B2 (en) * 2018-01-26 2023-06-13 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
IL300824A (en) * 2018-01-26 2023-04-01 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
MA51672A (fr) * 2018-01-26 2020-12-02 Exelixis Inc Composés destinés au traitement des troubles kinases-dépendants
PE20211757A1 (es) * 2018-12-13 2021-09-07 Exelixis Inc Formas cristalinas y formas de sal de un inhibidor de cinasa
CN113710322A (zh) * 2019-01-25 2021-11-26 埃克塞里艾克西斯公司 用于治疗激酶依赖性病症的化合物
AU2019449809A1 (en) * 2019-06-03 2021-12-16 Exelixis, Inc. Crystalline salt forms of a kinase inhibitor
AR119069A1 (es) * 2019-06-04 2021-11-24 Exelixis Inc Compuestos para el tratamiento de trastornos dependientes de quinasas
US20230192619A1 (en) * 2020-04-30 2023-06-22 Exelixis, Inc. Processes for the Preparation of a Kinase Inhibitor
JP2023536264A (ja) * 2020-07-31 2023-08-24 エグゼリクシス， インコーポレイテッド がんの治療のための組み合わせ
PE20240223A1 (es) * 2020-11-05 2024-02-16 Exelixis Inc Composiciones farmaceuticas de un inhibidor de cinasa
AR127561A1 (es) * 2021-11-03 2024-02-07 Exelixis Inc Compuestos para el tratamiento de trastornos dependientes de cinasas
WO2023122739A1 (en) * 2021-12-22 2023-06-29 Exelixis, Inc. Crystalline forms and salt forms of a kinase inhibitor

Also Published As

Publication number Publication date
WO2019148044A1 (en) 2019-08-01
EP3743070A1 (en) 2020-12-02
IL276032A (en) 2020-08-31
JP2021511360A (ja) 2021-05-06
CN111757735A (zh) 2020-10-09
AU2024205373A1 (en) 2024-08-22
US11542259B2 (en) 2023-01-03
SG11202006921PA (en) 2020-08-28
CN117402114A (zh) 2024-01-16
AU2019212801B2 (en) 2024-07-04
JP2023103446A (ja) 2023-07-26
CN117820226A (zh) 2024-04-05
PE20211203A1 (es) 2021-07-05
MA51673A (fr) 2020-12-02
CN111757735B (zh) 2023-09-22
CN117624045A (zh) 2024-03-01
CN117603138A (zh) 2024-02-27
JP7321165B2 (ja) 2023-08-04
US20210040076A1 (en) 2021-02-11
CO2020010465A2 (es) 2020-10-30
US20240043414A1 (en) 2024-02-08
AU2019212801A1 (en) 2020-08-20
UA128476C2 (uk) 2024-07-24
CR20230287A (es) 2023-07-26
PH12020551208A1 (en) 2021-05-17
KR20200115582A (ko) 2020-10-07
CL2020001931A1 (es) 2020-12-11
BR112020015201A2 (pt) 2020-12-29
MX2022016051A (es) 2023-02-01
IL300824A (en) 2023-04-01
MX2020007765A (es) 2020-09-25
CA3088200A1 (en) 2019-08-01
CR20200358A (es) 2021-02-22

Similar Documents

Publication Publication Date Title
PH12020551208A1 (en) Compounds for the treatment of kinase-dependent disorders
MX2022014351A (es) Compuestos para el tratamiento de trastornos dependientes de cinasas.
MX2021013110A (es) Compuestos heterociclicos como inhibidores de la cinasa ret.
PH12020550881A1 (en) Substituted bicyclic heterocyclic compounds as prmt5 inhibitors
MY202022A (en) Pyrrolotriazine compounds as tam inhibitors
EA201690391A1 (ru) Селективные модуляторы рецептора сфингозин-1-фосфата и способы хирального синтеза
EA201592033A1 (ru) 3-(2-АМИНОПИРИМИДИН-4-ИЛ)-5-(3-ГИДРОКСИПРОПИНИЛ)-1H-ПИРРОЛО[2,3-c]ПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ NIK ДЛЯ ЛЕЧЕНИЯ РАКА
WO2014194245A3 (en) Cdk8 inhibitors and uses thereof
MX2022001310A (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo.
EA201290329A1 (ru) Селективные гетрероциклические модуляторы рецептора сфингозин-1-фосфата
EA033236B1 (ru) Новые производные пиразола в качестве ингибиторов nik
PH12020551170A1 (en) Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
PH12020551390A1 (en) AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
EA201291055A1 (ru) Ингибиторы протеинтирозинкиназной активности и их применение для лечения глазных заболеваний
EA202090414A1 (ru) Соединения и их применение
MY197064A (en) Oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
MX2022003671A (es) Inhibidores de proteina cinasa i de interaccion con receptores para el tratamiento de enfermedades.
CA3139156A1 (en) Compounds for the treatment of kinase-dependent disorders
MX2023009059A (es) Antagonistas de gpr84 y usos de estos.
MX2022002443A (es) Compuestos inhibidores de perk.
EA202091790A1 (ru) Соединения для лечения киназозависимых расстройств
EA202091789A1 (ru) Соединения для лечения киназозависимых расстройств
EA202091424A1 (ru) Замещенные бициклические гетероциклические соединения в качестве ингибиторов prmt5
UA110978C2 (uk) Азетидинілфенілові, піридилові або піразинілкарбоксамідні похідні як інгібітори jak